This site is intended for healthcare professionals
Idiopathic Pulmonary Fibrosis (IPF) Learning Zone

Accredited CME

Read time: 60 mins
Last updated:19th Nov 2020
Published:16th Mar 2020

Early diagnosis and treatment of IPF is imperative to prevent disease progression and this CME module will help you to recognise symptoms and establish a definitive diagnosis.

Launch our interactive accredited CME module to find out more and test your knowledge on idiopathic pulmonary fibrosis (IPF). Discover the unmet needs for patients with this condition and the treatment options available to them.

IPF is the most common form of interstitial lung disease (ILD). If you want to find out more about different causes of ILD, an accredited CME module on recognising and treating autoimmune ILDs is also available.

Recognising and optimising care of IPF

Are you familiar with the symptoms of idiopathic pulmonary fibrosis (IPF)? Learn more about how to definitively diagnose IPF and find out how early diagnosis can benefit your patients. Plus improve your knowledge of the treatment options available to patients with IPF.

Receive 1 European CME credit (ECMEC®) for successful completion.

Accreditation date 16th March 2020.

Enrol

Section 5 Assessment and closing survey  5 mins
Introduction Introduction to the CME course 5 mins
Section 1 Burden and pathogenesis of IPF 15 mins
Section 2 Diagnosing IPF 15 mins
Section 3 Disease-modifying treatment 15 mins
Section 4 Non disease-modifying treatment 15 mins

Course overview

Quick baseline questions will be asked at the start of each section to assess your background and understanding. You will not be assessed on your responses to these questions.

Evaluation questions will be asked at the end of the module. You must achieve a score of 70% or above to pass the course and be able to print your certificate.

On completion of this course, participants will understand:

  • The underlying burden that IPF places on patients and carers
  • How to recognise symptoms and definitively diagnose IPF
  • The importance of early diagnosis in order to access disease-modifying treatment
  • The role of non disease-modifying treatment for patients with IPF

System Requirements

Faculty

Professor Elisabeth Bendstrup. Senior consultant and associate professor at the Department of Respiratory Diseases and Allergy at Aarhus University Hospital, Denmark. She is head of the hospital’s ILD unit (the Danish Centre for Interstitial Lung Diseases and Sarcoidosis), which is a tertiary referral centre for ILD and sarcoidosis.

Professor Martin Kolb. Martin Kolb is Moran Campbell Professor in Respiratory Medicine at McMaster University and the Firestone Institute for Respiratory Health in Hamilton, ON, Canada. Professor Kolb’s major research area is focused on mechanisms of lung injury, repair and fibrosis, particularly in IPF and he is Chief Editor of the European Respiratory Journal.

If you want to find out more about different causes of ILD, click below:

Accredited CME module on recognising and treating autoimmune ILDs 

Welcome: